Literature DB >> 9116220

Reduced immunoreactivity of adenylyl cyclase in dementia of the Alzheimer type.

M Yamamoto1, H Ozawa, T Saito, L Frölich, P Riederer, N Takahata.   

Abstract

The amounts of three adenylyl cyclase (AC) subtypes in membranes from brain obtained post-mortem from patients with dementia of Alzheimer type (DAT) and controls were studied by Western blotting using polyclonal antibodies. AC subtypes were characterized by preabsorption by complementary peptides, species difference, tissue distribution and by using AC-VI-transfected cells. Immunoreactivities of AC-I and AC-II subtypes, which are predominant in brain tissue were decreased 40.5% (p < 0.02) and 52.0% (p < 0.02), respectively in DAT compared with controls. No significant difference in immunoreactivity of AC-V/VI subtypes distributed in various other tissues was observed. Our results are the first to indicate that reduced levels of brain-specific AC subtypes occur in DAT.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9116220     DOI: 10.1097/00001756-199611250-00033

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  10 in total

1.  Diminished CRE-Induced Plasticity is Linked to Memory Deficits in Familial Alzheimer's Disease Mice.

Authors:  Nancy Bartolotti; Laura Segura; Orly Lazarov
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

2.  Complex noradrenergic dysfunction in Alzheimer's disease: Low norepinephrine input is not always to blame.

Authors:  Mary Gannon; Qin Wang
Journal:  Brain Res       Date:  2018-01-04       Impact factor: 3.252

3.  Ca2+/CaM-sensitive adenylyl cyclase activity is decreased in the Alzheimer's brain: possible relation to type I adenylyl cyclase.

Authors:  M Yamamoto; H Ozawa; T Saito; S Hatta; P Riederer; N Takahata
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

4.  Effects of a phosphodiesterase IV inhibitor rolipram on microsphere embolism-induced defects in memory function and cerebral cyclic AMP signal transduction system in rats.

Authors:  Akira Nagakura; Makiko Niimura; Satoshi Takeo
Journal:  Br J Pharmacol       Date:  2002-04       Impact factor: 8.739

5.  A possible mechanism for improvement by a cognition-enhancer nefiracetam of spatial memory function and cAMP-mediated signal transduction system in sustained cerebral ischaemia in rats.

Authors:  Satoshi Takeo; Makiko Niimura; Keiko Miyake-Takagi; Akira Nagakura; Tomoko Fukatsu; Tsuyoshi Ando; Norio Takagi; Kouichi Tanonaka; Junko Hara
Journal:  Br J Pharmacol       Date:  2003-02       Impact factor: 8.739

Review 6.  CREB signals as PBMC-based biomarkers of cognitive dysfunction: A novel perspective of the brain-immune axis.

Authors:  Nancy Bartolotti; Orly Lazarov
Journal:  Brain Behav Immun       Date:  2019-01-12       Impact factor: 7.217

7.  Real-time monitoring of intracellular cAMP during acute ethanol exposure.

Authors:  Ratna Gupta; Emily Qualls-Creekmore; Masami Yoshimura
Journal:  Alcohol Clin Exp Res       Date:  2013-06-03       Impact factor: 3.455

Review 8.  Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease.

Authors:  Elisa Zuccarello; Erica Acquarone; Elisa Calcagno; Elentina K Argyrousi; Shi-Xian Deng; Donald W Landry; Ottavio Arancio; Jole Fiorito
Journal:  Biochem Pharmacol       Date:  2020-01-21       Impact factor: 5.858

9.  Role of an adenylyl cyclase isoform in ethanol's effect on cAMP regulated gene expression in NIH 3T3 cells.

Authors:  Rebecca A Hill; Wu Xu; Masami Yoshimura
Journal:  Biochem Biophys Rep       Date:  2016-09-03

10.  Synaptic and memory dysfunction induced by tau oligomers is rescued by up-regulation of the nitric oxide cascade.

Authors:  Erica Acquarone; Elentina K Argyrousi; Manon van den Berg; Walter Gulisano; Mauro Fà; Agnieszka Staniszewski; Elisa Calcagno; Elisa Zuccarello; Luciano D'Adamio; Shi-Xian Deng; Daniela Puzzo; Ottavio Arancio; Jole Fiorito
Journal:  Mol Neurodegener       Date:  2019-06-27       Impact factor: 14.195

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.